Korean Firm signs Deal with Iranian Pharma

Under the agreement, Dong-A ST will immediately share its production technology of two therapies — growth hormone injection Growtropin and leukopenia therapy Leucostim — with the Tehran-based company. Rooyan Darou will also be granted a license to make and sell the Korean firm’s infertility drug Gonadopin and anemia treatment Eporon.

The terms of the deal have not been disclosed.

The Iranian government plans to localize the production of biopharmaceuticals for the next five years and increase the proportion of domestic production to 75 percent, according to the Korean firm. Iran’s pharma market is expected to grow by 6.4 percent annually to reach US$3.59 billion by 2025.